M
Manel Sabaté
Researcher at University of Barcelona
Publications - 607
Citations - 26779
Manel Sabaté is an academic researcher from University of Barcelona. The author has contributed to research in topics: Stent & Myocardial infarction. The author has an hindex of 63, co-authored 549 publications receiving 23775 citations. Previous affiliations of Manel Sabaté include Complutense University of Madrid & Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
Gilles Montalescot,Udo Sechtem,Stephan Achenbach,Felicita Andreotti,Chris Arden,Andrzej Budaj,Raffaele Bugiardini,Filippo Crea,Thomas Cuisset,Carlo Di Mario,J. Rafael Ferreira,Bernard J. Gersh,Anselm K. Gitt,Jean-Sébastien Hulot,Nikolaus Marx,Lionel H. Opie,Matthias Pfisterer,Eva Prescott,Frank Ruschitzka,Manel Sabaté,Roxy Senior,David P. Taggart,Ernst E. van der Wall,Christiaan J. Vrints,José Luis Zamorano,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Veronica Dean,Christi Deaton,Çetin Erol,Robert Fagard,Roberto Ferrari,David Hasdai,Arno W. Hoes,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Patrizio Lancellotti,Aleš Linhart,Petros Nihoyannopoulos,Massimo F Piepoli,Piotr Ponikowski,Per Anton Sirnes,Juan Tamargo,Michal Tendera,Adam Torbicki,William Wijns,Stephan Windecker,Marco Valgimigli,Marc J. Claeys,Norbert Donner-Banzhoff,Herbert Frank,Christian Funck-Brentano,Oliver Gaemperli,José Ramón González-Juanatey,Michalis Hamilos,Steen Husted,Stefan James,Kari Kervinen,Steen Dalby Kristensen,Aldo P. Maggioni,Axel R. Pries,Francesco Romeo,Lars Rydén,Maarten L. Simoons,Ph. Gabriel Steg,Adam Timmis,Aylin Yildirir +68 more
TL;DR: The If Inhibitor Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Dysfunction is evaluated as well as patients with Diabetes mellitus for Optimal management of Multivessel disease.
Journal ArticleDOI
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Christoph Stettler,Christoph Stettler,Simon Wandel,Sabin Allemann,Adnan Kastrati,Marie Claude Morice,Albert Schömig,Matthias Pfisterer,Gregg W. Stone,Martin B. Leon,José Suárez de Lezo,Jean-Jacques Goy,Seung-Jung Park,Manel Sabaté,Maarten J. Suttorp,Henning Kelbæk,Christian Spaulding,Maurizio Menichelli,Paul Vermeersch,Maurits T. Dirksen,Pavel Cervinka,Anna Sonia Petronio,Alain J Nordmann,Peter Diem,Bernhard Meier,Marcel Zwahlen,Stephan Reichenbach,Sven Trelle,Stephan Windecker,Peter Jüni,Peter Jüni +30 more
TL;DR: A network meta-analysis with a mixed-treatment comparison method to combine direct within-trial comparisons between stents with indirect evidence from other trials while maintaining randomisation found sirolimus-eluting stents seem to be clinically better than bare-metal and paclitaxel-eluted stents.
Journal ArticleDOI
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
Adnan Kastrati,Julinda Mehilli,Jürgen Pache,Christoph Kaiser,Marco Valgimigli,Henning Kelbæk,Maurizio Menichelli,Manel Sabaté,Maarten J. Suttorp,Dietrich Baumgart,Melchior Seyfarth,M Pfisterer,Albert Schömig +12 more
TL;DR: The use of sirolimus-eluting stents does not have a significant effect on overall long-term survival and survival free of myocardial infarction, as compared with bare-metal stents, but there is a sustained reduction in the need for reintervention after the use.
Journal ArticleDOI
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis
Tullio Palmerini,Giuseppe Biondi-Zoccai,Diego Della Riva,Christoph Stettler,Diego Sangiorgi,Fabrizio D'Ascenzo,Takeshi Kimura,Carlo Briguori,Manel Sabaté,Hyo-Soo Kim,Antoinette de Waha,Elvin Kedhi,Pieter C. Smits,Christoph Kaiser,Gennaro Sardella,Antonino G.M. Marullo,Ajay J. Kirtane,Martin B. Leon,Gregg W. Stone +18 more
TL;DR: In randomised studies completed to date, CoCr-EES has the lowest rate of stent thrombosis within 2 years of implantation and if confirmed in future randomised trials, represents a paradigm shift.
Journal ArticleDOI
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease
Gregg W. Stone,Joseph F. Sabik,Patrick W. Serruys,Charles A. Simonton,Philippe Généreux,John D. Puskas,David E. Kandzari,Marie Claude Morice,Nicholas Lembo,W. Morris Brown,David P. Taggart,Adrian P. Banning,Béla Merkely,Ferenc Horkay,Piet W. Boonstra,Ad J. van Boven,Imre Ungi,Gábor Bogáts,Samer Mansour,Nicolas Noiseux,Manel Sabaté,José L. Pomar,Mark Hickey,Anthony H. Gershlick,Paweł Buszman,Andrzej Bochenek,Erick Schampaert,Pierre Pagé,Ovidiu Dressler,Ioanna Kosmidou,Roxana Mehran,Stuart J. Pocock,A. Pieter Kappetein +32 more
TL;DR: In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years.